WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 1, 2005--Formulatrix announced today that it has entered into a global licensing agreement with the research division of Novartis for Formulatrix’ Rock Maker software. Rock Maker will integrate Novartis’ entire crystallization process including experimental design, liquid handling, imaging, and data management. Jeremy Stevenson, President of Formulatrix stated, “This deal reinforces our belief that Rock Maker is the premier software solution for automating protein crystallization. This sale also provides us with additional resources to invest into the continued development of Rock Maker.” Formulatrix specializes in providing technology that automates the protein crystallization process, a key part of structure based drug discovery. Formulatrix has established itself as one of the leading players in this field with customers would wide including leading pharmaceuticals, biotechnology, and academic institutions. For further information, please visit www.formulatrix.com
